Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK.
To determine whether cyclosporine (0.05%) can safely and effectively accelerate corneal nerve regeneration after LASIK, thereby facilitating faster recovery of corneal sensitivity.



This prospective, randomized, single-center clinical study comprised 44 eyes of 22 patients scheduled to undergo bilateral LASIK. One eye was randomly assigned to receive cyclosporine drops twice daily for 3 months in addition to standard postoperative LASIK medication. Corneal sensitivity was measured using the Cochet-Bonnet esthesiometer in four areas outside and five areas inside the LASIK flap preoperatively and at 1 day, 1 week, 1 month, and 3 months postoperatively. Safety parameters of best spectacle-corrected visual acuity and the incidence of adverse events were also collected.



For all four points outside the LASIK flap, normal corneal sensitivity was maintained throughout the study. In addition, no significant difference was found between the cyclosporine-treated eyes and the control eyes at these points. All points within the LASIK flap except the point closest to the hinge demonstrated profound corneal hypoesthesia at 1 day, 1 week, and 1 month postoperatively with no differences noted between the control and cyclosporine-treated eyes. These same points had statistically significantly greater corneal sensitivity in the cyclosporine group relative to the control group (P< or =.011) at 3 months postoperatively.



Cyclosporine was shown to significantly improve corneal sensitivity at 3 months after LASIK, which suggests that topical cyclosporine promotes enhanced corneal nerve regeneration.
Peyman
Gholam A
GA
Department of Ophthalmology, University of Arizona, Phoenix, Ariz., USA.
Sanders
Donald R
DR
Batlle
Juan F
JF
Féliz
Rafael
R
Cabrera
Ginny
G
D000328:Adult; D003315:Cornea / Q000294:innervation*; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006987:Hypesthesia / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D009416:Nerve Regeneration / Q000187:drug effects*; D009882:Ophthalmic Nerve / Q000502:physiology; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D011182:Postoperative Care; D011446:Prospective Studies; D012029:Refraction, Ocular / Q000502:physiology; D013524:Surgical Flaps; D014792:Visual Acuity / Q000502:physiology
D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine